: Revolution Medicines to acquire EQRx in deal that will add $1 billion in cash to its balance sheet to fund R&D

Revolution Medicines Inc. RVMD said Tuesday it has reached a definitive agreement to acquire EQRx Inc. EQRX in an all-cash deal that’s expected to add more than $1 billion in net cash to its balance sheet. Revolution Medicines specializes in therapies for RAS-addicted cancers, or those that are caused by mutations in RAS genes. The company is expecting to use the proceeds of the $1 billion to fund late-stage development of RAS inhibitor drug candidates. Under the terms of the board-approved deal, EQRx shareholders will receive shares to be determined closer to the shareholder vote on the deal using an exchange-ratio formula equal to about 7.7 million Revolution shares as well as shares equal to $870 million that will be discounted based on Revolution’s share price at that time. “This singular acquisition of a sizable quantum of capital signifies the growing confidence we have in our RAS-focused drug candidate pipeline, and substantially increases our capacity to continue advancing high-performing oncology assets, particularly our priority clinical-stage RAS(ON) Inhibitors, RMC-6236, RMC-6291 and RMC-9805, with the potential to create significant long-term value for our shareholders,” said REvolution’s CEO Dr. Mark A. Goldsmith in a statement. The deal is expected to close in November.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Previous post Walmart is bringing ads to an aisle near you as retailers chase new money-makers
Next post : Norwegian Cruise’s stock drops after earnings beat expectations, but current-quarter outlook disappoints